Guadecitabine in Treating Patients With Higher-Risk Myelodysplastic Syndromes

NCT02131597 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

100

Enrollment

OTHER

Sponsor class

Conditions

High Risk Myelodysplastic Syndrome

Interventions

DRUG: Guadecitabine

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]